Clinical Trial Update: Effect of Ensifentrine on Sputum Markers of Inflammation in COPD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Ensifentrine's effect on sputum inflammatory markers in chronic obstructive pulmonary disease, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Ensifentrine (ensifentrine)

Snippet

Sponsor: Verona Pharma plc | Conditions: COPD | Phase 2 | Status: RECRUITING